Advertisement

Index by Author

October 1998; 47 (10)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Alberiche, M

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  2. Andersen, H U

    • Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes October 1998 47:1602-1608; doi:10.2337/diabetes.47.10.1602

  3. Andersen, T

    • Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes October 1998 47:1657-1658; doi:10.2337/diabetes.47.10.1657

  4. Andersson, A

    • Capillary blood pressure in syngeneic rat islets transplanted under the renal capsule is similar to that of the implantation organ. Diabetes October 1998 47:1586-1593; doi:10.2337/diabetes.47.10.1586

B

  1. Barbetti, F

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  2. Bashan, N

    • Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes October 1998 47:1562-1569; doi:10.2337/diabetes.47.10.1562

  3. Behn, P S

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  4. Bernal-Mizrachi, E

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  5. Boden, G

    • Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes October 1998 47:1609-1612; doi:10.2337/diabetes.47.10.1609

  6. Boitard, C

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

  7. Bonadonna, R C

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  8. Bonora, E

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  9. Boppart, M D

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

  10. Buongiorno, A

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  11. Burk, S H

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

C

  1. Caillat-Zucman, S

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

  2. Carlsen, R C

    • Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes October 1998 47:1637-1642; doi:10.2337/diabetes.47.10.1637

  3. Carlsson, P O

    • Capillary blood pressure in syngeneic rat islets transplanted under the renal capsule is similar to that of the implantation organ. Diabetes October 1998 47:1586-1593; doi:10.2337/diabetes.47.10.1586

  4. Carpino, P A

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  5. Chayen, S

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  6. Chen, X

    • Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes October 1998 47:1609-1612; doi:10.2337/diabetes.47.10.1609

  7. Chester, M W

    • Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes October 1998 47:1613-1618; doi:10.2337/diabetes.47.10.1613

  8. Cronin, M J

    • Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes October 1998 47:1637-1642; doi:10.2337/diabetes.47.10.1637

D

  1. D'Adamo, M

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  2. Danforth, E, Jr

    • Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes October 1998 47:1555-1561; doi:10.2337/diabetes.47.10.1555

  3. Daniels, M B

    • Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes October 1998 47:1613-1618; doi:10.2337/diabetes.47.10.1613

  4. Dobbins, R L

    • Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes October 1998 47:1613-1618; doi:10.2337/diabetes.47.10.1613

  5. Drijfhout, J W

    • HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes October 1998 47:1594-1601; doi:10.2337/diabetes.47.10.1594

  6. Dubois, D

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

  7. Dufresne, S D

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

  8. Dupont, S

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

  9. Duprat, L

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

E

  1. Echwald, S M

    • Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes October 1998 47:1657-1658; doi:10.2337/diabetes.47.10.1657

  2. Egger, G

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  3. Elias, K A

    • Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes October 1998 47:1637-1642; doi:10.2337/diabetes.47.10.1637

F

  1. Flatt, P R

    • Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes October 1998 47:1619-1624; doi:10.2337/diabetes.47.10.1619

  2. Froguel, P

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

G

  1. Gant, T G

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  2. Geluk, A

    • HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes October 1998 47:1594-1601; doi:10.2337/diabetes.47.10.1594

  3. Giaccari, A

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  4. Gibson, L

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

  5. Giragossian, C

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  6. Glaser, B

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  7. Goodyear, L J

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

H

  1. Hemi, R

    • Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes October 1998 47:1562-1569; doi:10.2337/diabetes.47.10.1562

  2. Hirshman, M F

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

  3. Horton, E S

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

I

  1. Iqbal, N

    • Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes October 1998 47:1609-1612; doi:10.2337/diabetes.47.10.1609

J

  1. Jansson, L

    • Capillary blood pressure in syngeneic rat islets transplanted under the renal capsule is similar to that of the implantation organ. Diabetes October 1998 47:1586-1593; doi:10.2337/diabetes.47.10.1586

K

  1. Källskog, O

    • Capillary blood pressure in syngeneic rat islets transplanted under the renal capsule is similar to that of the implantation organ. Diabetes October 1998 47:1586-1593; doi:10.2337/diabetes.47.10.1586

  2. Kanety, H

    • Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes October 1998 47:1562-1569; doi:10.2337/diabetes.47.10.1562

  3. Karlsen, A E

    • Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes October 1998 47:1602-1608; doi:10.2337/diabetes.47.10.1602

  4. Kelly, C M

    • Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes October 1998 47:1619-1624; doi:10.2337/diabetes.47.10.1619

  5. Kiechl, S

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  6. Kwon, Y

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

L

  1. Larsen, C M

    • Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes October 1998 47:1602-1608; doi:10.2337/diabetes.47.10.1602

  2. Lenzen, S

    • Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes October 1998 47:1578-1585; doi:10.2337/diabetes.47.10.1578

  3. Leonetti, F

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  4. Levy, C B

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  5. Liblau, R

    • Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes October 1998 47:1570-1577; doi:10.2337/diabetes.47.10.1570

  6. Lortz, S

    • Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes October 1998 47:1578-1585; doi:10.2337/diabetes.47.10.1578

M

  1. Mandrup-Poulsen, T

    • Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes October 1998 47:1537-1543; doi:10.2337/diabetes.47.10.1537
    • Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes October 1998 47:1602-1608; doi:10.2337/diabetes.47.10.1602

  2. Maroccia, E

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  3. Martin, W H

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  4. Mauricio, D

    • Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes October 1998 47:1537-1543; doi:10.2337/diabetes.47.10.1537

  5. McDevitt, H O

    • Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes October 1998 47:1570-1577; doi:10.2337/diabetes.47.10.1570

  6. McGarry, J D

    • Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes October 1998 47:1613-1618; doi:10.2337/diabetes.47.10.1613

  7. McPherson, R K

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  8. Meyer, J

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  9. Mooney, M H

    • Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes October 1998 47:1619-1624; doi:10.2337/diabetes.47.10.1619

  10. Muggeo, M

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  11. Munday, R

    • Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes October 1998 47:1578-1585; doi:10.2337/diabetes.47.10.1578

N

  1. Napoli, R

    • Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes October 1998 47:1549-1554; doi:10.2337/diabetes.47.10.1549

  2. Nielsen, K

    • Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes October 1998 47:1602-1608; doi:10.2337/diabetes.47.10.1602

O

  1. O'Harte, F P

    • Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes October 1998 47:1619-1624; doi:10.2337/diabetes.47.10.1619

  2. Oberhollenzer, F

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  3. Ottenhoff, T H

    • HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes October 1998 47:1594-1601; doi:10.2337/diabetes.47.10.1594

P

  1. Parker, J C

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  2. Pedersen, O

    • Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes October 1998 47:1657-1658; doi:10.2337/diabetes.47.10.1657

  3. Permutt, M A

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  4. Potashnik, R

    • Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes October 1998 47:1562-1569; doi:10.2337/diabetes.47.10.1562

R

  1. Ravussin, E

    • Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes October 1998 47:1555-1561; doi:10.2337/diabetes.47.10.1555

  2. Roep, B O

    • HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes October 1998 47:1594-1601; doi:10.2337/diabetes.47.10.1594

  3. Rudich, A

    • Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes October 1998 47:1562-1569; doi:10.2337/diabetes.47.10.1562

S

  1. Sbraccia, P

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  2. Schloot, N C

    • HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes October 1998 47:1594-1601; doi:10.2337/diabetes.47.10.1594

  3. Singer, S M

    • Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes October 1998 47:1570-1577; doi:10.2337/diabetes.47.10.1570

  4. Snitker, S

    • Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes October 1998 47:1555-1561; doi:10.2337/diabetes.47.10.1555

  5. Stein, D T

    • Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes October 1998 47:1613-1618; doi:10.2337/diabetes.47.10.1613

  6. Stewart, T A

    • Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes October 1998 47:1637-1642; doi:10.2337/diabetes.47.10.1637

  7. Sytwu, H K

    • Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes October 1998 47:1570-1577; doi:10.2337/diabetes.47.10.1570

  8. Sørensen, T I

    • Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes October 1998 47:1657-1658; doi:10.2337/diabetes.47.10.1657

T

  1. Tamburrano, G

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

  2. Tao, T

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  3. Targher, G

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  4. Tataranni, P A

    • Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes October 1998 47:1555-1561; doi:10.2337/diabetes.47.10.1555

  5. Tiedge, M

    • Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes October 1998 47:1578-1585; doi:10.2337/diabetes.47.10.1578

  6. Timsit, J

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

  7. Tirosh, A

    • Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes October 1998 47:1562-1569; doi:10.2337/diabetes.47.10.1562

  8. Tisch, R

    • Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes October 1998 47:1570-1577; doi:10.2337/diabetes.47.10.1570

  9. Treadway, J L

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  10. Tybjaerg-Hansen, A

    • Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes October 1998 47:1657-1658; doi:10.2337/diabetes.47.10.1657

V

  1. van Meijgaarden, K E

    • HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes October 1998 47:1594-1601; doi:10.2337/diabetes.47.10.1594

  2. VanVolkenburg, M A

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  3. Vestergaard, P

    • Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes October 1998 47:1630-1636; doi:10.2337/diabetes.47.10.1630

  4. Vionnet, N

    • No association between the Friedreich's ataxia gene and NIDDM in the French population. Diabetes October 1998 47:1654-1656; doi:10.2337/diabetes.47.10.1654

W

  1. Wadt, K A

    • Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes October 1998 47:1602-1608; doi:10.2337/diabetes.47.10.1602

  2. Wasson, J

    • Isolation and characterization of the human PAX4 gene. Diabetes October 1998 47:1650-1653; doi:10.2337/diabetes.47.10.1650

  3. Weyer, C

    • Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes October 1998 47:1555-1561; doi:10.2337/diabetes.47.10.1555

  4. Willeit, J

    • Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes October 1998 47:1643-1649; doi:10.2337/diabetes.47.10.1643

  5. Wilson, J E

    • Distinguishing the type I and type II isozymes of hexokinase: the need for a reexamination of past practice. Diabetes October 1998 47:1544-1548; doi:10.2337/diabetes.47.10.1544

Y

  1. Yang, X D

    • Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes October 1998 47:1570-1577; doi:10.2337/diabetes.47.10.1570

Z

  1. Zorretta, D

    • Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes October 1998 47:1625-1629; doi:10.2337/diabetes.47.10.1625

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement